Ocular Hypertension Completed Phase 3 Trials for Tafluprost (DB08819)

Also known as: Intraocular pressure raised / Ocular Hypertension (OHT) / Hypertension Ocular / Hypertension, Ocular / Intraocular pressure high / Intraocular hypertension / Ocular Hypertension (OH) / Elevated intraoccular pressure / Intraocular pressure increased / IOP increased / Raised IOP / Ocular tension increased / Tension ocular increased / Pressure intraocular increased / Increased intraocular pressure

IndicationStatusPhase
DBCOND0074237 (Ocular Hypertension)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01254604Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)Treatment
NCT00596791Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye DropsTreatment
NCT01087671Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsTreatment
NCT01026831Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)Treatment
NCT00918346Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationTreatment
NCT01306461Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsTreatment
NCT01292460Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesTreatment
NCT01342081DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%Treatment